Phase II study of KX2-391 ointment 1%, a novel field treatment for actinic keratosis, based on Src/tubulin polymerization inhibition
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY(2018)
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY(2018)